TET2 mutations are specific for CMML (P < 0.0001), whereas SETBP1 and CSF3R mutations are significantly more frequent in aCML (P < 0.0001, and P = 0.0074, respectively). This evidence concerns the gene TET2 and atypical chronic myeloid leukemia, BCR-ABL1 negative.